Abstract
Chronic lymphedema is both a risk factor for and consequence of erysipelas (cellulitis). We report a case of a 62-year-old woman with rheumatoid arthritis treated with etanercept and prednisone, who developed chronic periorbital lymphedema 2 months after Group A beta-hemolytic streptococcus infection of the face. She had significant ptosis OS and thickened, hyperpigmented periorbital skin. Biopsies were consistent with chronic lymphedema. Of note, on 6 months follow-up, the patient's appearance was improved though she still had residual ptosis. A period of extended observation may be warranted in these cases.
MeSH terms
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy
-
Chronic Disease
-
Drug Therapy, Combination
-
Erysipelas / complications*
-
Erysipelas / diagnosis
-
Erysipelas / drug therapy
-
Etanercept
-
Facial Dermatoses / diagnosis
-
Facial Dermatoses / drug therapy
-
Facial Dermatoses / etiology*
-
Female
-
Humans
-
Immunoglobulin G / therapeutic use
-
Lymphedema / diagnosis
-
Lymphedema / drug therapy
-
Lymphedema / etiology*
-
Magnetic Resonance Imaging
-
Middle Aged
-
Orbital Diseases / diagnosis
-
Orbital Diseases / drug therapy
-
Orbital Diseases / etiology*
-
Prednisone / therapeutic use
-
Receptors, Tumor Necrosis Factor / therapeutic use
Substances
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Etanercept
-
Prednisone